Ferring Pharmaceuticals A/S

Research activities extend to men with unexplained impairment of semen quality, with interest in how fertility-directed treatment may influence the chance of conception in partners.

• Idiopathic male infertility
• Oligoasthenozoospermia
• Spontaneous pregnancy outcomes

This area reflects a broader focus on reproductive medicine for both male and female infertility.

The sponsor supports oncology research in non-muscle-invasive bladder cancer, including disease settings with recurrence risk, carcinoma in situ, and papillary disease.

• High-risk BCG-unresponsive NMIBC
• Intermediate-risk NMIBC
• Bladder cancer recurrence and progression

There is also interest in treatment approaches for patients after local bladder tumour resection and in disease control where standard intravesical options have limited benefit.

Uro-oncology research includes low-grade upper tract urothelial carcinoma, with attention to disease management in the renal pelvis and related urinary tract sites.

• LG-UTUC
• Renal pelvis administration
• Urothelial cancer control

This area complements the sponsor’s broader interest in urothelial malignancies affecting the bladder and upper urinary tract.

The sponsor also funds research in inflammatory gastrointestinal disease, indicating therapeutic interest beyond reproductive and uro-oncology settings.

• Gastrointestinal inflammation
• Chronic intestinal disease
• Digestive tract inflammation

This area adds a gastroenterology dimension to the company’s clinical research portfolio.